ライフサイエンスコーパス: atherectomy

1 of estrogen and intervention (angioplasty or atherectomy).

2 additional treatment (balloon angioplasty or atherectomy).

3 roposed to be predictive of restenosis after atherectomy.

4 malities associated with rotational coronary atherectomy.

5 nt risk factor for restenosis after coronary atherectomy.

6 atherectomy and adjunct directional coronary atherectomy.

7 45 +/- 87 degrees after directional coronary atherectomy.

8 tervention, particularly in those undergoing atherectomy.

9 of restenosis after coronary angioplasty and atherectomy.

10 atherectomy and adjunct directional coronary atherectomy.

11 lected from patients undergoing percutaneous atherectomy.

12 onary angiography performed six months after atherectomy.

13 nderwent PTCA, laser ablation, or rotational atherectomy.

14 ronary atherectomy and high speed rotational atherectomy.

15 gioplasty, laser ablation, and/or rotational atherectomy.

16 coronary angioplasty or directional coronary atherectomy.

17 rotic lesions were obtained from directional atherectomy.

18 duced platelet aggregation during rotational atherectomy.

19 the changes in the application of rotational atherectomy.

20 utcomes for patients treated with rotational atherectomy.

21 excimer laser (0.89 [0.29-2.7]), rotational atherectomy (0.96 [0.53-1.7]), and vascular brachytherap

22 n-Q wave myocardial infarctions by 71% after atherectomy (15.4% for placebo vs. 4.5% for bolus and in

23 oon angioplasty (73% vs. 50%) and rotational atherectomy (16.1% vs. 8.3%) were used more often in sma

24 treatment included stents (50%), directional atherectomy (24%), and balloon angioplasty (20%).

25 - 16%, p < 0.001) and lower after rotational atherectomy (27 +/- 15%, p < 0.001).

26 to stents (18.5% vs. 41.9%) and directional atherectomy (3.7% vs. 13.5%), conventional balloon angio

27 for adjunctive angioplasty after extraction atherectomy (37 +/- 16%, p < 0.001) and excimer laser an

28 fuse lesions, underwent balloon angioplasty, atherectomy, additional stenting, or a combination of th

29 ific stenoses, but the ability of rotational atherectomy alone to optimize lumen dimensions in large

30 y 10% of these procedures include rotational atherectomy, although the national average rate of stent

31 PAR-4 expression was increased in carotid atherectomies and saphenous vein specimens from diabetic

32 ed (1) human lesions obtained by directional atherectomy and (2) experimentally induced neointima for

33 ectomy than in those treated with rotational atherectomy and adjunct balloon angioplasty.

34 son with 208 lesions treated with rotational atherectomy and adjunct coronary angioplasty was perform

35 lesions in 163 patients by use of rotational atherectomy and adjunct directional coronary atherectomy

36 mmediate and long-term results of rotational atherectomy and adjunct directional coronary atherectomy

37 Rotablator atherectomy and adjunctive PTCA significantly improve di

38 od flow velocity before and after Rotablator atherectomy and after adjunctive percutaneous translumin

39 evaluated 22 patients undergoing rotational atherectomy and compared their wall motion abnormalities

40 the mechanisms by which rotational coronary atherectomy and coronary angioplasty produce their effec

41 synergistic relationship between rotational atherectomy and directional coronary atherectomy in the

42 was lower in lesions treated with rotational atherectomy and directional coronary atherectomy than in

43 ptotic cell death has been reported in human atherectomy and endarterectomy specimens and for neointi

44 Rotational atherectomy, extraction atherectomy and excimer laser angioplasty can facilitate

45 gioplasty was also observed after extraction atherectomy and excimer laser angioplasty for ostial les

46 unctive balloon angioplasty after rotational atherectomy and excimer laser angioplasty provides bette

47 alities are common after rotational coronary atherectomy and have a longer duration than those observ

48 d, which includes PTCA, directional coronary atherectomy and high speed rotational atherectomy.

49 The combination of rotational atherectomy and intra-coronary stent placement is betwee

50 angioplasty is often used immediately after atherectomy and laser angioplasty to further enlarge lum

51 directional (n = 19) and rotational (n = 6) atherectomy and stent implantation (n = 11).

52 eviews the existing literature on rotational atherectomy and stent implantation for complex lesions a

53 ularization of ULMT is required, directional atherectomy and stenting appear to be the preferred tech

54 grees to 166 +/- 93 degrees after rotational atherectomy and to 145 +/- 87 degrees after directional

55 coronary angioplasty or directional coronary atherectomy and whose peak CK levels did not exceed twic

56 coprotein IIb/IIIa inhibitor; none underwent atherectomy, and all had final TIMI 3 flow.

57 y angioplasty, laser angioplasty, rotational atherectomy, and/or stent implantation.

58 Mechanical thrombectomy and atherectomy are efficient methods of arterial recanaliza

59 ic total occlusions or debulking plaque with atherectomy are less rigorously studied and have niche r

60 30 human peripheral arteries by directional atherectomy at times ranging from 13 days to 36 months a

61 tients with 90 lesions underwent directional atherectomy before coronary stenting.

62 othesis that plaque removal with directional atherectomy before stent implantation may lower the inte

63 Rotational atherectomy burr time was longer in the patients who dev

64 ) have demonstrated modest benefits favoring atherectomy but at a cost of increased acute ischemic co

65 igh-risk coronary angioplasty or directional atherectomy but increases bleeding complications.

66 curs commonly after coronary angioplasty and atherectomy, but the causes of restenosis are poorly und

67 und analysis to determine whether rotational atherectomy causes ablation of non-calcified atheroscler

68 he hypothesis that more aggressive "optimal" atherectomy could be performed safely to produce larger

69 (PEB) angioplasty, stenting, and directional atherectomy (DA) have provided new options for the treat

70 Vessel preparation with directional atherectomy (DA) potentially improves outcomes of DCB.

71 16 patients undergoing directional coronary atherectomy (DCA) and control samples from the internal

72 ious clinical trials of directional coronary atherectomy (DCA) have failed to show significant improv

73 in patients treated by directional coronary atherectomy (DCA) in the Coronary Angioplasty Versus Exc

74 EAT-I demonstrated that directional coronary atherectomy (DCA) resulted in higher rates of early comp

75 Directional coronary atherectomy (DCA) specimens from 63 lesions were analyze

76 Previous directional coronary atherectomy (DCA) trials have shown no significant reduc

77 ss serial changes after directional coronary atherectomy (DCA).

78 sms of restenosis after directional coronary atherectomy (DCA).

79 Optimal DCA was defined as using a 7F atherectomy device and adjunctive PTCA if necessary to a

80 minimally invasive technique, the Silverhawk Atherectomy device.

81 tment methods for resistant lesions, such as atherectomy devices and cutting balloons.

82 Although atherectomy devices have been used to treat bifurcation

83 ng stents; excisional, laser, and rotational atherectomy devices; devices for crossing total occlusio

84 Rotational atherectomy effectively ablates noncalcified plaque in n

85 onary angioplasty, directional or rotational atherectomy, excimer laser angioplasty, or Palmaz-Schatz

86 Rotational atherectomy, extraction atherectomy and excimer laser an

87 METHODS AND DEFINITIVE AR study (Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to I

88 Directional atherectomy followed by coronary stenting could be perfo

89 dural, hospital and clinical outcomes of TEC atherectomy followed by immediate Palmaz-Schatz coronary

90 ss of transluminal extraction catheter (TEC) atherectomy followed by immediate Palmaz-Schatz coronary

91 TEC atherectomy followed by immediate Palmaz-Schatz coronary

92 laser angioplasty, rotational or directional atherectomy followed by stenting, whereas 106 patients w

93 recruited 89 patients who underwent coronary atherectomy for de novo atherosclerosis (n=55) or in-ste

94 ted facilitated angioplasty after rotational atherectomy for ostial, eccentric, ulcerated and calcifi

95 20 patients undergoing directional coronary atherectomy for stable angina were analyzed for immunore

96 ive patients undergoing directional coronary atherectomy for symptomatic coronary artery disease.

97 ssue specimens were retrieved by directional atherectomy from 10 patients in whom in-stent restenosis

98 ery) retrieved by using directional coronary atherectomy from 25 patients at 0.5 to 23 (mean, 5.7) mo

99 Samples acquired by directional coronary atherectomy from 25 patients with type 2 diabetes and 18

100 ry of baseline wall motion in the rotational atherectomy group (153 min, 95% confidence interval [CI]

101 on was significantly lower in the rotational atherectomy group than in the coronary angioplasty group

102 Patients undergoing directional atherectomy had a lower baseline risk for acute complica

103 sions that develop restenosis after coronary atherectomy have more macrophages and smooth muscle cell

104 used in 9% of procedures, laser in 30%, and atherectomy in 16%, and thrombolytic therapy was adminis

105 15% and before stenting in 43%), directional atherectomy in 4% and angioplasty alone in 7%.

106 patients (alone in 30% and after rotational atherectomy in 43%), rotational atherectomy in 58% (alon

107 r rotational atherectomy in 43%), rotational atherectomy in 58% (alone in 15% and before stenting in

108 ver, after changes in reimbursement, PVI and atherectomy in outpatient facilities and office-based cl

109 farction, in patients undergoing directional atherectomy in the Evaluation of c7E3 for the Prevention

110 2,099 patients who underwent angioplasty or atherectomy in the Evaluation of IIb/IIIa platelet recep

111 ational atherectomy and directional coronary atherectomy in the treatment of calcific lesions.

112 coronary angioplasty (PTCA) (with or without atherectomy) in the side branch, and Gp 2 included 54 pa

113 The use of atherectomy increased 2-fold in outpatient hospital sett

114 esion revascularization was a larger overall atherectomy index (84% vs. 59%, p = 0.048).

115 Rotational atherectomy is a safe and feasible technique for treatme

116 Rotational atherectomy is best suited for treating calcific stenose

117 Rotational atherectomy is currently the preferred treatment for hea

118 rials of balloon angioplasty versus coronary atherectomy, laser angioplasty, or cutting balloon ather

119 techniques such as directional or rotational atherectomy, laser angioplasty, or thrombectomy devices

120 te the randomized controlled experience with atherectomy, laser, or atherotomy versus balloon angiopl

121 After adjunct directional coronary atherectomy, lumen area increased even more to 6.7 +/- 2

122 TEC atherectomy may reduce distal embolization, and stenting

123 lesions alone (n = 541) or after extraction atherectomy (n = 277), rotational atherectomy (Rotablato

124 was the performance of directional coronary atherectomy (odds ratio, 4.1; P < .0001), followed by th

125 or without stenting, laser angioplasty, and atherectomy of the femoral, popliteal, and tibial vessel

126 We evaluated the effects of orbital atherectomy on intraluminal paclitaxel delivery to human

127 VSMCs were derived from coronary atherectomies or from normal coronary arteries from tran

128 vals, 1.21-1.96; P<0.001), use of rotational atherectomy (OR, 2.37; 95% confidence intervals, 1.80-3.

129 nary angioplasty, laser ablation, rotational atherectomy, or additional stenting (36% of lesions).

130 directional coronary atherectomy, rotational atherectomy, or excimer laser angioplasty.

131 1 SD) to 3.9 +/- 1.1 mm(2) after rotational atherectomy, owing to a decrease in plaque plus media ar

132 Treatment with atherectomy plus PTCA resulted in lower postprocedure re

133 or debulking (with rotational or directional atherectomy) plus adjunctive PTCA (n = 40).

134 ross all types of PVI, whereas mean costs of atherectomy procedures in outpatient and office-based cl

135 l safety and long-term results of rotational atherectomy (RA) followed by low-pressure balloon dilata

136 Rotational atherectomy (RA) is an important interventional tool for

137 oronary angioplasty (ELCA) versus rotational atherectomy (RA), both followed by adjunct PTCA; 119 pat

138 angioplasty (BA), repeat stent or rotational atherectomy (RA).

139 n the coronary angioplasty group (rotational atherectomy rate constant 0.069 +/- 0.079/min vs. corona

140 Directional atherectomy-related non-Q wave myocardial infarction app

141 sound Restenosis (SURE) Trial and in Optimal Atherectomy Restenosis Study (OARS) were enrolled in thi

142 ultrasound (IVUS) substudy of OARS (Optimal Atherectomy Restenosis Study) was designed to assess the

143 Since Rotablator atherectomy results in luminal enlargement by plaque pul

144 t and early patients treated with rotational atherectomy revealed an increase in the complexity of pa

145 g to the treatment strategy: CBA, rotational atherectomy (ROTA), additional stenting (STENT), and per

146 extraction atherectomy (n = 277), rotational atherectomy (Rotablator) (n = 211) or excimer laser angi

147 l coronary angioplasty, directional coronary atherectomy, rotational atherectomy, or excimer laser an

148 substantially less u-PA were present in the atherectomy samples from subjects with diabetes.

149 All human coronary atherectomy samples stained positive for Ang II and macr

150 ed in microvessels in the human aorta and in atherectomy samples.

151 om 1.310-3.450 pmol/micromol phospholipid in atherectomy specimens compared with 0.045-0.115 pmol/mic

152 t binds specifically to HA was used to stain atherectomy specimens from 29 human restenotic lesions (

153 A total of 47 coronary atherectomy specimens from patients with diabetes mellit

154 mellitus were examined and compared with 48 atherectomy specimens from patients without diabetes.

155 This study of atherectomy specimens investigated the in vivo role of L

156 Immunohistochemical studies on human atherectomy specimens revealed the presence of fVIII in

157 Coronary atherectomy specimens were definitely positive in 66 (73

158 Eighteen coronary atherectomy specimens with restenosis after PTCA from pa

159 ients with DM were compared with 18 coronary atherectomy specimens with restenosis after PTCA from pa

160 V) DNA is present in restenotic lesions from atherectomy specimens.

161 andomized Stent Implantation, Postrotational Atherectomy (SPORT) trial.

162 angioplasty, stent deployment or rotational atherectomy strategies.

163 of each artery was treated using an orbital atherectomy system (OAS) under simulated blood flow and

164 ational atherectomy and directional coronary atherectomy than in those treated with rotational athere

165 After atherectomy, the mean (+/- SD) minimal luminal diameter

166 After rotational atherectomy, the minimal lumen cross-sectional area incr

167 tion abnormalities after rotational coronary atherectomy, the prevalence and duration of these wall m

168 Macrophages are increased in coronary atherectomy tissue from primary lesions that develop res

169 ed on trichrome-stained sections of coronary atherectomy tissue.

170 sing both cultured human CASMCs and coronary atherectomy tissues, we studied the roles of osteopontin

171 The Balloon vs Optimal Atherectomy Trial (BOAT) was conducted to evaluate wheth

172 n the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT) I and II studies.

173 first Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) influenced subsequent pract

174 n the Coronary Angioplasty Versus Excisional Atherectomy Trial with angiographic follow-up were conta

175 wave myocardial infarction with directional atherectomy use compared with PTCA.

176 c occlusive disease intervention, rotational atherectomy use, number of stents, hypertension, and fem

177 ents were imaged before and after rotational atherectomy using intravascular ultrasound systems incor

178 tudy used pre-rotational and post-rotational atherectomy volumetric intravascular ultrasound analysis

179 ([mean +/- SD] 10.3 +/- 6 min for rotational atherectomy vs. 9.6 +/- 4.2 min for coronary angioplasty

180 Directional coronary atherectomy was associated with a larger acute gain in b

181 Stand-alone atherectomy was attempted, and adjunct therapy was used

182 Debulking with excimer laser or atherectomy was performed in 133 patients (139 lesions)

183 intervention in the EPIC trial, directional atherectomy was performed in 197 (10%).

184 Before atherectomy was performed, we measured blood levels of a

185 90 symptomatic patients undergoing coronary atherectomy were tested for the presence of Chlamydia sp

186 Women undergoing atherectomy who received estrogen had a significantly lo

187 We compared an early registry of rotational atherectomy with a recent registry to examine the evolut

188 in patients undergoing directional coronary atherectomy with a variety of control specimens and comp

189 r the treatment of true bifurcation lesions, atherectomy with adjunctive PTCA is safe, improves acute

190 Directional atherectomy with deep arterial wall resection as practic

191 Randomized trials comparing directional atherectomy with percutaneous transluminal coronary angi

192 Rotational atherectomy with the Rotablator catheter has improved pe

193 ndergoing balloon angioplasty or directional atherectomy within 72 h of presentation with either unst